InSite Vision to Report Second Quarter Financial Results on August 3, 2010

ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Incorporated (OTCBB:INSV) announced today that it will release financial results for the second quarter ended June 30, 2010 on Tuesday, August 3, 2010.

Company management will host a conference call beginning at 4:30 p.m. ET/1:30 p.m. PT to discuss results and review recent accomplishments. Investors can submit questions prior to the conference call via the company's website at www.insitevision.com through the "Information Request" tab on the Investor Relations page.

Analysts and investors can listen to the conference call by dialing (877) 407-8035 for domestic callers and (201) 689-8035 for international callers. A telephone replay will be available following the conclusion of the call by dialing (877) 660-6853 for domestic callers and (201) 612-7415 for international callers. All callers will need to enter the account number 286 and conference ID 354491.

The live conference call will also be webcast and available on the Investor Relations page of the company's website at www.insitevision.com. A press release detailing second quarter 2010 financial results will also be posted to the company's website and furnished to the Securities and Exchange Commission on a Form 8-K.

About InSite Vision

InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The company’s product portfolio utilizes InSite Vision’s proven DuraSite® bioadhesive polymer core technology, an innovative platform that extends the duration of drug retention on the surface of the eye, thereby reducing frequency of treatment and improving the efficacy of topically delivered drugs. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Inspire Pharmaceuticals, and Besivance™ (besifloxacin ophthalmic suspension) 0.6%, marketed by InSite Vision’s licensee Bausch & Lomb and their partner Pfizer Inc. InSite Vision’s clinical-stage ophthalmic product pipeline includes ISV-502 and ISV-305 for the treatment of eye infections, and ISV-303 for pain and swelling associated with ocular surgery. For further information on InSite Vision, please visit www.insitevision.com.



CONTACT:

InSite Vision
Louis Drapeau, 510-747-1220
Chief Executive Officer
[email protected]
or
Media inquiries
BCC Partners
Michelle Corral, 415-794-8662

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Optical

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.